What is the clinical evidence from this study?

Population: Thromboinflammatory disorders. Intervention: QK10 vs. Low molecular weight heparin (LMWH). Primary outcome: Antithrombotic efficacy and bleeding risk.

What question did this study set out to answer?

The research aims to explore the role of IL-1β in thrombosis and develop a peptide that inhibits its effects on coagulation.

April 17, 2026Cellular and Molecular Life SciencesOpen Access

Inhibiting thromboinflammation with a designed peptide that blocks the IL-1β-FXIa axis uncouples antithrombosis from bleeding risk

View Full Paper

Ask AI

Bookmark

Key result

Novel peptide QK10 matches LMWH antithrombotic efficacy with significantly lower bleeding risk in preclinical models.

Key Points

The research aims to explore the role of IL-1β in thrombosis and develop a peptide that inhibits its effects on coagulation.
Developed a model of IL-1β-FXIa interaction.
Derived peptide QK10 to block IL-1β's effect on FXIa.
Conducted thrombosis and bleeding assays to evaluate efficacy and safety.
QK10 showed significant antithrombotic effects comparable to low molecular weight heparin (LMWH).
QK10 had a lower bleeding risk compared to LMWH.
QK10 demonstrated anti-stroke efficacy in ischemic stroke models.

Structured PICO

Population

Preclinical thrombosis and ischemic stroke models

Intervention

QK10 (inhibitory peptide blocking IL-1β-FXIa interaction)

Comparator

Low molecular weight heparin (LMWH)

Outcome

Antithrombotic efficacy and bleeding risksurrogate

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

The designed peptide QK10 uncouples antithrombosis from bleeding risk by targeting the IL-1β-FXIa axis, offering a novel therapeutic approach for thrombo-inflammatory conditions.

Cite This Study

Wang et al. (2026) studied Thromboinflammatory disorders. QK10 vs. Low molecular weight heparin (LMWH) was evaluated on Antithrombotic efficacy and bleeding risk. The inhibitory peptide QK10 exhibited significant antithrombotic efficacy comparable to LMWH in multiple thrombosis models, but with a significantly lower bleeding risk.

synapsesocial.com/papers/69e1cefb5cdc762e9d857e5b https://doi.org/10.1007/s00018-026-06205-1

View Full Paper

Ask AI

Bookmark

Implication

The designed peptide QK10 uncouples antithrombosis from bleeding risk by targeting the IL-1β-FXIa axis, offering a novel therapeutic approach for thrombo-inflammatory conditions.

Inhibiting thromboinflammation with a designed peptide that blocks the IL-1β-FXIa axis uncouples antithrombosis from bleeding risk

Key Points

Structured PICO

Discussion

Implication

Cite This Study

Inhibiting thromboinflammation with a designed peptide that blocks the IL-1β-FXIa axis uncouples antithrombosis from bleeding risk

Key Points

Structured PICO

Discussion

Implication

Cite This Study

Also Consider

Also Consider